| Study Period | 2019 - 2032 |
| Market Size in 2025 | USD 3.2 Billion |
| Market Size in 2026 | USD 3.4 Billion |
| Market Size by 2032 | USD 4.7 Billion |
| Projected CAGR | 5.6% |
| Largest Region | North America |
| Fastest-Growing Region | Asia-Pacific |
| Market Structure | Semi-Consolidated |
Explore the market potential with our data-driven report
The thyroid cancer diagnostics market size will be an estimated USD 3.2 billion for 2025, and it will grow by 5.6% during 2026–2032, to reach USD 4.7 billion by 2032.
The major factors responsible for the growth of the market include rising incidence of thyroid cancer globally, technological advancements in diagnostic imaging and molecular testing, growing awareness about early detection, and increasing healthcare expenditure across regions. The global thyroid cancer incidence is projected to rise from 233,847 cases in 2019 to 305,078 by 2030, representing an approximate 30.46% increase, which directly drives demand for advanced diagnostic solutions.
The integration of artificial intelligence in ultrasound imaging and molecular diagnostic platforms has revolutionized the assessment of thyroid nodules. Approximately 20% of thyroid fine needle aspirations yield indeterminate results, creating substantial demand for molecular testing to guide clinical management. Recent developments in ultrasound elastography and multiparametric ultrasound combine B-mode, Doppler, and elastography to provide comprehensive nodule assessments, enhancing diagnostic accuracy significantly.
The papillary carcinoma category holds the largest market share, of 80%, in 2025, as it stands out as the predominant form of thyroid cancer. This dominance stems from the cancer type's relatively favorable prognosis when detected early, high incidence rates globally, and well-established diagnostic protocols that have been refined over decades. The availability of standardized imaging guidelines, molecular testing options, and targeted treatment protocols, such as thyroidectomy and radioiodine therapy, further reinforces its prominence in the diagnostic market.
The follicular carcinoma category will have the highest CAGR, of 6.0%, due to the advancements in molecular diagnostic technologies specifically designed to differentiate this cancer type from benign follicular adenomas. The development of mutation panels targeting NRAS, HRAS, and PAX8-PPARG rearrangements has improved preoperative diagnosis accuracy. The growing recognition of follicular variant papillary thyroid carcinoma as a distinct entity requiring tailored diagnostic approaches further drives demand for specialized testing in this segment.
The cancer types analyzed in this report are:
The imaging category holds the largest market share, of 65%, in 2025. Ultrasound serves as the first-line diagnostic modality due to its non-invasive nature, wide availability, cost-effectiveness, and absence of radiation exposure. The integration of advanced imaging technologies, including ultrasound elastography, computed tomography, magnetic resonance imaging, and positron emission tomography, provides a comprehensive anatomical and functional assessment of thyroid lesions. Ultrasound is not only used for imaging but also for guided fine-needle aspirations.
The molecular diagnostics category will have the highest CAGR, of 5.8%, owing to the increasing adoption of precision medicine approaches and the need to reduce unnecessary surgeries for indeterminate thyroid nodules. The development of next-generation sequencing platforms, gene expression classifiers, and mutation panels has revolutionized the diagnostic workflow. These tests provide actionable genomic information that informs treatment decisions and risk stratification. Molecular diagnostics enable clinicians to differentiate benign from malignant nodules more accurately, reducing patient exposure to invasive procedures and optimizing surgical planning. Advances in liquid biopsy and circulating tumor DNA (ctDNA) analysis further support non-invasive monitoring and early detection of recurrence.
The diagnostic techniques analyzed in this report are:
The solid category holds the larger market share, of 70%, in 2025, driven by the widespread use of fine-needle aspiration biopsy as the gold standard for evaluating thyroid nodules. Solid tissue samples obtained through biopsy provide cellular material for cytological examination and molecular testing, enabling accurate diagnosis and risk stratification. The procedure's minimally invasive nature, high diagnostic yield, and ability to provide material for ancillary testing ensure its continued dominance.
The liquid category will have the higher CAGR during the forecast period, due to emerging applications of liquid biopsy technology. Blood-based testing offers several advantages, including non-invasiveness, ability to perform serial monitoring, and detection of circulating tumor markers. Research into cell-free DNA, circulating thyroid cancer cells, and thyroid-specific biomarkers in blood and other body fluids shows promise for early detection and disease monitoring applications.
The sample types analyzed in this report are:
The hospital laboratories category holds the largest market share in 2025, as it serves as the primary center for thyroid cancer diagnosis, equipped with advanced imaging equipment, cytopathology departments, and molecular diagnostic capabilities. Their integration within comprehensive cancer care centers enables seamless coordination between diagnostic and therapeutic services. The high volume of thyroid evaluations performed in hospital settings, combined with access to multidisciplinary tumor boards and specialized endocrinologists, ensures their market leadership.
The cancer diagnostics centers category will have the highest CAGR, during the forecast period, driven by substantial funding for thyroid cancer research, clinical trials evaluating novel diagnostic biomarkers, and the development of next-generation diagnostic platforms. Academic medical centers and dedicated cancer research institutions play a crucial role in validating emerging technologies before their widespread clinical adoption. Collaborations between research institutes and diagnostic companies accelerate the translation of scientific discoveries into commercially available diagnostic tests.
The end users analyzed in this report are:
The largest category is above 50 years, with 45% share, as this cancer incidence peaks in adults above 50, particularly between 55–59 years. This group accounts for the majority of new diagnoses and mortality due to more aggressive disease subtypes and comorbidities. Diagnostic demand is high, with routine imaging, cytology, and molecular testing commonly employed for timely detection.
The fastest‑growing category is 30–50 years, with a CAGR during the forecast period. Incidence is rising most rapidly in adults aged 30–50, especially women, driven by hormonal, genetic, and environmental risk factors. Early detection through ultrasound, fine-needle aspiration, and molecular panels is increasingly emphasized. This demographic shows growing demand for preventive screening and personalized diagnostic approaches, reflecting global trends in younger adult thyroid cancer cases.
These age groups are analyzed:
Women lead the market with 80% share as they are diagnosed with thyroid cancer about three times more often than men. They dominate diagnostic demand for imaging, cytology, and molecular panels, particularly in their reproductive years when incidence peaks.
Males are the faster-growing category, with a CAGR of 5.9%. One global study found a higher age‑standardized incidence annual growth for men (EAPC ~1.59) than for women (EAPC ~0.68). Men also tend to present with more aggressive disease, thus boosting more advanced diagnostic work‑ups.
These patient genders are considered:
Drive strategic growth with comprehensive market analysis
North America holds the largest market share, of 45%, in 2025. This dominance is attributed to advanced healthcare infrastructure, high healthcare expenditure, widespread availability of cutting-edge diagnostic technologies, favorable reimbursement policies, and strong emphasis on early cancer detection.
In 2025, there will be about 44,020 fresh diagnoses of thyroid cancer in the U.S., making it the ninth most common cancer in women. The American healthcare system's focus on precision medicine and personalized treatment approaches has accelerated the adoption of molecular diagnostic platforms. The presence of leading diagnostic technology companies, research institutions, and comprehensive cancer centers creates an ecosystem conducive to innovation and rapid technology adoption.
In Canada, thyroid cancer is the seventh most common cancer in women, with 6,600 recent cases in 2024, as per the Canadian Cancer Society. Canadian healthcare authorities have implemented systematic thyroid screening programs and invested in upgrading diagnostic infrastructure. Radiation exposure is associated with increased thyroid cancer incidence in Canada, driving demand for advanced diagnostic services. Both countries benefit from well-established clinical guidelines, trained healthcare professionals specializing in thyroid disorders, and patient advocacy groups promoting awareness and early detection.
Asia-Pacific will have the highest CAGR, of 5.7%, driven by rapidly expanding healthcare infrastructure, increasing healthcare expenditure, growing disease awareness, large patient populations, and rising adoption of advanced diagnostic technologies.
South Korea represents another high-incidence country in the region, implementing comprehensive thyroid cancer screening programs that have dramatically increased detection rates. Japan's aging population and advanced healthcare system contribute to sustained demand for thyroid diagnostics.
Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) also mandates rigorous clinical validation and post-market reporting for thyroid diagnostic devices, supporting reliable adoption of advanced imaging and molecular testing technologies. As per GLOBACAN, thyroid cancer accounted for 16,419 new cases and 2,193 deaths in Japan in 2024.
India's large population, improving healthcare access, and growing middle class with increasing health insurance coverage present substantial growth opportunities. As per the Press Information Bureau, the occurrence of thyroid cancer is consistently rising on a global scale, whereas the death rate has stayed constant. In India, the incidence of thyroid cancer is 5.4 per hundred thousand individuals.
Europe has a significant market, supported by well-established healthcare systems, comprehensive cancer registries, and robust medical device regulations ensuring quality standards. The region's emphasis on evidence-based medicine and adherence to clinical practice guidelines drives appropriate utilization of thyroid diagnostics. Germany, France, the U.K., Italy, and Spain maintain sophisticated healthcare infrastructure with universal health coverage, facilitating access to diagnostic services. The European Union's medical device regulations ensure that only high-quality, clinically validated diagnostic technologies reach the market.
Germany serves as a major market within Europe, characterized by its advanced medical technology sector, strong research institutions, and high healthcare spending. The country's tumor centers provide comprehensive multidisciplinary care, including advanced diagnostic capabilities. France and the U.K. similarly maintain robust thyroid cancer diagnostic programs integrated within national healthcare systems. The region's collaborative research networks facilitate rapid dissemination of diagnostic innovations and standardization of clinical approaches.
The countries of the market are as follows:
The market is semi-consolidated due to the presence of several major multinational diagnostic companies alongside regional players and emerging biotechnology firms specializing in molecular diagnostics. The market dynamics reflect a balance between established imaging and laboratory diagnostic giants and innovative molecular diagnostic companies introducing next-generation testing platforms. Major diagnostic companies leverage their extensive distribution networks, established relationships with healthcare providers, comprehensive product portfolios spanning imaging systems to molecular tests, and substantial R&D budgets to maintain competitive positions. However, specialized molecular diagnostic companies have carved significant market share through innovative testing platforms that address unmet clinical needs. Leading players maintain market positions through continuous product innovation, strategic collaborations with healthcare institutions, geographical expansion into emerging markets, and comprehensive service offerings.
Want a report tailored exactly to your business need?
Request CustomizationLeading companies across industries trust us to deliver data-driven insights and innovative solutions for their most critical decisions. From data-driven strategies to actionable insights, we empower the decision-makers who shape industries and define the future. From Fortune 500 companies to innovative startups, we are proud to partner with organisations that drive progress in their industries.
Working with P&S Intelligence and their team was an absolute pleasure – their awareness of timelines and commitment to value greatly contributed to our project's success. Eagerly anticipating future collaborations.
McKinsey & Company
India
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws
Customize the Report to Align with Your Business Objectives
Request the Free Sample Pages